`
`Group Art Unit: 1649
`
`Examiner: Ulm, John D. (during pendency)
`
`Confirmation No.: 5197
`
`In re Application of:
`
`LUKASHEV et al.
`
`Application No.: 12/526,296 (abandoned)
`
`§ 371(c) Date: January 13, 2011
`
`For:
`
`Treatment for Multiple Sclerosis
`
`vvvvvvvvvv
`
`Commissioner for Patents
`PO. Box 1450
`
`Alexandria, VA 22313-1450
`
`Commissioner:
`
`AMENDMENT TO SPECIFICATION
`
`Further to Biogen’s Miscellaneous Motion 1 (Requesting Entry of ADS and/or
`
`Amendment in Biogen Priority Application No. 12/526,296) filed in Patent Interference No.
`
`106,023, Patentee respectfully requests that the specification be amended as shown below.
`
`Page 1 of 3
`
`Biogen Exhibit 2110
`Mylan v. Biogen
`IPR 2018-01403
`
`
`
`AMENDMENT TO THE SPECIFICATION:
`
`Please amend the specification as follows:
`
`Application No.: 12/526,296
`
`On page 1, below the title of the application, please add the following new paragraph:
`
`CROSS REFERENCE TO RELATED APPLICATIONS
`
`This application is the US. National Phase of lntemational Application No.
`
`PCT/USZOO8/001602, filed February 7, 2008, which claims the benefit of US. Provisional
`
`Application 60/888,921, filed February 8, 2007.
`
`Page 2 of3
`
`
`
`Application No.: 12/526,296
`
`REMARKS
`
`Further to Biogen’s the Miscellaneous Motion 1 identified above and for the reasons set
`
`forth therein, Patentee respectfully requests entry of this amendment.
`
`Please charge any additional required fees to Deposit Account No. 06-0916.
`
`Respectfully submitted,
`
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, L.L.P.
`
`Dated: July 20, 2015
`
`By:
`
`[Michele C. Bosch/
`Michele C. Bosch
`
`Reg. No. 40,524
`(202) 408-4000
`
`Page 3 of3
`
`